Literature DB >> 21677678

Leukaemia: targeted therapy re-enABLed?

Darren J Burgess.   

Abstract

Entities:  

Year:  2011        PMID： 21677678     DOI： 10.1038/nrc3099

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Authors:  Cihangir Duy; Christian Hurtz; Seyedmehdi Shojaee; Leandro Cerchietti; Huimin Geng; Srividya Swaminathan; Lars Klemm; Soo-mi Kweon; Rahul Nahar; Melanie Braig; Eugene Park; Yong-mi Kim; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; J Jessica Yu; Nora Heisterkamp; Thomas G Graeber; Hong Wu; B Hilda Ye; Ari Melnick; Markus Müschen
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962
  1 in total
  2 in total

1.  Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.

Authors:  Xiaojuan Yang; Jiuxia Pang; Na Shen; Fei Yan; Lai-Chu Wu; Aref Al-Kali; Mark R Litzow; Yong Peng; Robert J Lee; Shujun Liu
Journal:  Oncotarget       Date:  2016-06-14

2.  Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia.

Authors:  Julia González-Rincón; Sagrario Gómez; Nerea Martinez; Kevin Troulé; Javier Perales-Patón; Sophia Derdak; Sergi Beltrán; Belén Fernández-Cuevas; Nuria Pérez-Sanz; Sara Nova-Gurumeta; Ivo Gut; Fátima Al-Shahrour; Miguel A Piris; José A García-Marco; Margarita Sánchez-Beato
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.